ITOCO (ITMC) to Bring Molecular Diagnostic Technologies and a DNA Test Kit Platform for Virus and Other Disease Causing Organisms to Market
– Upcoming Bio-Tech Company with Established Industry Partnerships.
– Focus on Key Topics Including Diagnostics, Gene Therapy, Virus and Disease Control.
– New DNA Test Kit for Rapid Detection of Viruses.
– International Marketing Agreement with ACGT DNA Technologies.
August 4, 2020 (Viz Release) – – ITOCO Inc. (OTC: ITMC) is on a mission to be a global leader in developing, producing and distributing Bio-Tech related technologies and methodologies in a compliant, environmentally friendly manner. Recently, through a corporate investment initiative, ITMC management became aware of a number of key Bio-Tech research and development opportunities and the company is now pursuing a number of joint venture and co-development partnerships in this vitally important business area. ITMC has an attractive share structure for investors with and OS of about 128 million and a public float of only about 39 million shares out.
Bio-Tech is at the frontline of modern science. It is a leading technology that directly addresses the most serious challenges of our time such as hunger, energy, and disease. Healthcare has benefited tremendously from Bio-Tech especially in the areas of oncology, immunology, and regenerative therapies. These areas will be a special focus for ITMC.
On July 16th ITMC announced the launch of it Bio-Tech Blog at https://blog.itoco.net which covers topics related to Diagnostics, Gene Therapy, Viruses, Disease control, as well as other market-related trends. ITMC Nanoguard technology uses the well known anti-bacterial properties of Silver and Copper to protect and sanitize. Also, ITMC, in partnership with Sterilize Solutions, offers a full and continuously expanding range of purification, sanitization and protective products in an easy to use centralized website hub.
– ITOCO to Bring Molecular Diagnostic Technologies and a DNA Test Kit Platform for Virus and Other Disease Causing Organisms to Market
On August 4th ITMC announced potentially game changing news for the fight against infectious diseases. ITMC reported that the company would bring advanced molecular diagnostic technologies and a patented DNA test kit platform to market via a co-development agreement with ACGT DNA Technologies.
ITMC will have various rights to market the technologies, initially to the state of New York, and as well as Canada, Mexico, and Germany. Other territories may be added to the arrangement over time. Profits from these territories shall be split equally with ACGT net of expenses. Additionally, ITMC and ACGT shall establish a laboratory to co-develop products that can be used on the platform.
Most importantly, the ACGT DNA Test Kit platform uses patented proprietary DNA and RNA analysis techniques to detect viruses and other disease-causing organisms. Test times have the potential to be significantly faster than current widely used technology.
This new development has the potentially to offer the rapid test results that is so urgently needed today to help control the spread pandemic viruses and safeguard many thousands of lives in the months to come, especially as the school season resumes. The system is at the advanced prototype stage and is available for demonstrative purposes.
ITMC also reported that the company continues to make good progress on other partnerships and initiatives that will be announced in the coming weeks.
For more information on ITOCO Inc. (OTC: ITMC) visit: https://www.itoco.net/